LifeMD, Inc. Common Stock (LFMD) Stock
NASDAQ · LFMD
Key stats
- Market cap
- $114.37M
- Price / Earnings ratio
- -41.0x
- EPS (TTM)
- -$0.05
- Volume
- Loading
- 52-week high
- $6.53
- 52-week low
- $2.46
Source: third-party data provider, as of October 16, 2026
Compare with LFMD
Recent news

Zacks Investment Research
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?
LFMDSeptember 16, 2026
Zacks Investment Research
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?
LFMD

MarketBeat
LifeMD Q2 Earnings Call Highlights
LFMDAugust 6, 2026
MarketBeat
LifeMD Q2 Earnings Call Highlights
LFMD

Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates
LFMDAugust 6, 2026
Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates
LFMD

Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LFMDMay 6, 2026
Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LFMD
Technical indicators
- RSI 14
- 24.57
- MACD 12/26/9
- -0.20
- EMA 9 of MACD
- -0.16
- MACD histogram
- -0.03
- SMA 50
- $3.10
- Price below SMA 50
- EMA 50
- $3.13
- Price below EMA 50
- SMA 200
- $3.76
- Price below SMA 200
- EMA 200
- $3.71
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Strong Sell0
Sell0
Hold0
Buy3
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2025
233M154M77M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
84M56M28M0
Revenue to Profit
2025$194.1M
Revenue$0.0
Cost of revenue$166.3M
Gross profit$0.0
Operating expenses$14.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?
LFMDSeptember 16, 2026
Zacks Investment Research
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?
LFMD

MarketBeat
LifeMD Q2 Earnings Call Highlights
LFMDAugust 6, 2026
MarketBeat
LifeMD Q2 Earnings Call Highlights
LFMD

Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates
LFMDAugust 6, 2026
Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates
LFMD

Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LFMDMay 6, 2026
Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LFMD

Zacks Investment Research
LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?
LFMDApril 21, 2026
Zacks Investment Research
LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?
LFMD

Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
LFMDMarch 9, 2026
Zacks Investment Research
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
LFMD

Stocktwits
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List
LFMDJanuary 6, 2026
Stocktwits
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List
LFMD

Zacks Investment Research
TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio?
LFMDNovember 20, 2025
Zacks Investment Research
TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio?
LFMD

Zacks Investment Research
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now?
LFMDOctober 27, 2025
Zacks Investment Research
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now?
LFMD

Reuters
LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers
LFMDSeptember 30, 2025
Reuters
LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers
LFMD
About LifeMD, Inc. Common Stock
No description available.
SectorHealthcare
IndustryHealth Information Services
Employees347
CEOMr. Justin Schreiber
IPO DateJan 2, 2001
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Justin Schreiber | Chairman & CEO | 1983 |
| Ms. Shayna Webb Dray | Chief Operating Officer | 1987 |
| Mr. Atul Kavthekar | Chief Financial Officer | — |
| Mr. Stefan Galluppi | Chief Innovation Officer | 1987 |
| Ms. Maria E. Stan CPA | Chief Accounting Officer & Controller | 1975 |
| Mr. Umesh Sripad | Chief Technology Officer | — |
| Mr. Eric H. Yecies | Chief Legal Officer, General Counsel & Corporate Secretary | 1978 |
| Mr. Shane Biffar | Chief Compliance Officer & Deputy General Counsel | 1983 |
| Mr. Chris Pisano | Chief Marketing Officer | 1975 |
| Mr. James Porte | SVP of Care Center Operations | — |
Fundamentals
Valuation
Price-to-sales ratio0.58
Price-to-book value14.95
Profitability
Return on Equity-25.00%
Return on Assets-4.00%
Return on Sales0.00%
Gross margin (latest quarter)88.82%
EBITDA$10.39M
Trading
Average volume777,955
Source: third-party data provider, as of October 16, 2026
Technical indicators
- RSI 14
- 24.57
- MACD 12/26/9
- -0.20
- EMA 9 of MACD
- -0.16
- MACD histogram
- -0.03
- SMA 50
- $3.10
- Price below SMA 50
- EMA 50
- $3.13
- Price below EMA 50
- SMA 200
- $3.76
- Price below SMA 200
- EMA 200
- $3.71
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $8.00
- Average
- $8.67
- High
- $9.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.4 | -22.2 | -3.0 | |||||||||
| 2022 | -11.4 | -3.4 | -0.8 | -37.2 | -13.5 | -8.9 | +19.8 | +4.5 | -17.2 | +10.1 | +13.0 | -21.1 |
| 2023 | +4.8 | -14.0 | -4.0 | -2.4 | +24.2 | +99.5 | -1.0 | -13.3 | +47.1 | +0.0 | +20.7 | +6.8 |
| 2024 | -33.7 | +37.2 | +28.5 | +17.0 | -29.1 | -8.9 | +4.9 | -22.1 | +4.0 | -19.5 | +52.5 | -24.3 |
| 2025 | +6.5 | -7.9 | +15.0 | +35.5 | +64.1 | +6.0 | -20.7 | -37.7 | +10.0 | -12.4 | -33.3 | -4.5 |
| 2026 | -7.2 | -18.6 | +24.1 | +30.7 | -14.4 | -10.8 | -22.9 | -17.2 | -6.5 | -16.8 |
Compare stocks
Market cap
$114.37M
-
-
-
Price / Earnings ratio
-41.00
-
-
-
Price / Sales ratio
0.58
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
777,955
-
-
-
Earnings per share
$-0.05
-
-
-



